TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01583023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: 150mg daily for first week, 300mg daily thereafter for a total of 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: 150mg daily for first week, 300mg daily thereafter for a total of 8 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Repetitive Transcranial Magnetic Stimulation
Description: Daily left DLPFC, at 110% motor threshold, with a frequency of 10 Hz. Stimulation will be applied in 5-second trains with a 10-second inter-train interval, for 30 trains per session. This treatment will be provided for the first 4 weeks of the study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Repetitive Transcranial Magnetic Stimulation
Description: Daily left DLPFC, at 110% motor threshold, with a frequency of 10 Hz. Stimulation will be applied in 5-second trains with a 10-second inter-train interval, for 30 trains per session. This treatment will be provided for the first 4 weeks of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 150mg daily first week, 300mg daily thereafter for a total of 8 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham repetitive transcranial magnetic stimulation
Description: Sham rTMS will also begin their treatment 5 times a week for 4 weeks in junction with pharmacotherapy (Wellbutrin). Sham rTMS will be delivered at a frequency of 10 Hz and stimulation will be applied in 5-second trains with a 20-second inter-train interval, for 30 trains per session.
Study: NCT03614338

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Small changes weight loss program
Description: This intervention uses a small-changes approach to calorie reduction (operationalized as 6 100-calories changes per day) along with increasing leisure-time physical activity and self-regulation strategies to produce weight loss. The intervention will be delivered via 12 face-to-face group sessions.
Study: NCT02912468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab SAR231893 (REGN668)
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Solution~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate 50 micrograms
Description: Pharmaceutical form: Suspension (Nasal spray)~Route of administration: Intranasal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mometasone furoate 50 micrograms
Description: Pharmaceutical form: Suspension (Nasal spray)~Route of administration: Intranasal
Study: NCT03462134

Intervention type: OTHER
Intervention: Survey
Description: Survey amongst orthopaedic surgeons
Study: NCT02166957

Intervention type: PROCEDURE
Intervention: Recanalization
Description: All patients received clear and detailed information about the different steps, the benefits and the risks of the procedure they would undergo, and gave an informed consent.~The rendez-vous technique shared some common characteristics whatever the etiology and the length of esophageal disruption. First, prior to start the specific endoscopic management, all the patients needed to have undergone a surgical gastrostomy one month earlier in order to allow the retrograde access. This one-month delay was necessary to get it completely healed before using it for the procedure.~The principle of the combined anterograde retrograde approach is to get an endoscopic access to both the proximal and distal side of the obstruction in the purpose to achieve better and safer recanalization, which could be carried out with either transillumination or using a needle under x-rays guidance.

Intervention type: PROCEDURE
Intervention: Recanalization
Description: All patients received clear and detailed information about the different steps, the benefits and the risks of the procedure they would undergo, and gave an informed consent.~The rendez-vous technique shared some common characteristics whatever the etiology and the length of esophageal disruption. First, prior to start the specific endoscopic management, all the patients needed to have undergone a surgical gastrostomy one month earlier in order to allow the retrograde access. This one-month delay was necessary to get it completely healed before using it for the procedure.~The principle of the combined anterograde retrograde approach is to get an endoscopic access to both the proximal and distal side of the obstruction in the purpose to achieve better and safer recanalization, which could be carried out with either transillumination or using a needle under x-rays guidance.
Study: NCT02243774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core letter signed by Surgeon General
Description: The core letter provides information about influenza and the risks associated with it, incorporating a number of behavioral insights. All four letters evaluated in this study will contain the same tops and bodies that are included in the core letter, but the signature and P.S. tag region will differ among the various intervention groups. In this intervention, the core letter is signed by and includes a picture of the Surgeon General. The letter ends after the signature line and the space beneath the signature line is left blank where a P.S. tag region could be appended.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core letter signed by the Director of the National Vaccine Program
Description: The core letter is signed by and includes a picture of the Director of the National Vaccine Program. The letter ends after the signature line and the space beneath the signature line is left blank where a P.S. tag region could be appended.
Study: NCT02243774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core letter signed by Surgeon General + implementation prompt
Description: The core letter is signed by and includes a picture of the Surgeon General. Below the signature line of the core letter, an implementation intention prompt is provided in the P.S. tag region that invites the recipient to write in the day of week, month, day, and time at which he or she plans to get vaccinated.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core letter signed by SG + enhanced implementation prompt
Description: The core letter is signed by and includes a picture of the Surgeon General (SG). Below the signature line of the core letter, an enhanced implementation intention prompt is provided in the P.S. tag region that prompts recipients to decide now - by checking one of two boxes - indicating they will or will not get vaccinated. The options use language that highlights the losses incumbent in refusing to vaccinate. In addition, an implementation intention prompt is embedded into the checkbox for indicating a choice to be vaccinated.
Study: NCT04735042

Intervention type: DRUG
Intervention: Empagliflozin / Linagliptin or Dapagliflozin/Saxagliptin Pill
Description: association between SGLT2-inhibitor and DPP4-inhibitor

Intervention type: DRUG
Intervention: Empagliflozin or Dapagliflozin Pill
Description: SGLT2-inhibitor: diabetic oral drug with diuretic properties.
Study: NCT01735396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Abiraterone acetate 1000 mg orally daily (supplied as four 250 mg tablets) and prednisone 5 mg orally twice daily
Study: NCT01617317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperimmune intravenous immunoglobulin
Description: Single intravenous infusion of 0.4g/kg of H1N1 2009 H-IVIG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous immunoglobulin
Description: Single intravenous infusion of 0.4g/kg of simple IVIG
Study: NCT02733705

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: normal saline IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: fentanyl 0.5 mcg/kg ideal BW

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: propofol
Description: propofol infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: propofol infusion
Study: NCT01302561

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sucrose
Description: 5 g of sucrose twice daily for 24 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Galactooligosaccharide
Description: 2.5 g galactooligosaccharide plus 2.5 g sucrose twice daily for 24 weeks
Study: NCT01774318

Intervention type: OTHER
Group type: OTHER
Intervention: aEEG and conventional EEG measurement
Description: aEEG and conventional EEG measurement including video-polysomnography
Study: NCT00653549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torsemide
Description: Tablets, 20 mg, single-dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Demadex
Description: tablets, 20 mg, single-dose
Study: NCT04235634

Intervention type: DRUG
Intervention: Prostavasin
Description: Minimal invasive Cannulation of the Superior Mesenteric Artery (SMA) and subsequent intra-arterial application of prostaglandin E1 (Initial Bolus 20ug, followed by continuous Infusion of 60-80ug/24hr for 24-72hrs)
Study: NCT00695747

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2 Site procedure- Phacoemulsification/IOL and Trabeculectomy
Description: 2 Site Combined Procedure: in which a temporal clear cornea approach would be used for the cataract/IOL part of the procedure, and immediately thereafter the superior limbus would be employed for a limbus-based trabeculectomy
Study: NCT02055937

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate implant breast reconstruction
Description: Eligible patients will undergo radical mastectomy with axillary lymph nodes sampling followed by immediate and single-stage breast reconstruction using the acellular dermal matrix Strattice™
Study: NCT02467413

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAC
Description: (vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: BAC Matched Vehicle
Description: BAC Matched Vehicle
Study: NCT01916941

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prazosin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03107377

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EVO100
Description: 5 g dose applied up to 1 hour prior to coitus

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 g dose applied up to 1 hour prior to coitus
Study: NCT01351428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine
Description: 30-60 mg, twice daily
Study: NCT02415374

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Avenanthramides
Description: AVAs are a group of diphenolic acids that are found only in oats (Avena sativa). In this study, each dietary group of subjects will receive three cookies made with oat flour containing high-AVA (H-AVA, 229.56 mg/kg) and low-AVA (L-AVA, 32.69 mg/kg).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Avenanthramides
Description: AVAs are a group of diphenolic acids that are found only in oats (Avena sativa). In this study, each dietary group of subjects will receive three cookies made with oat flour containing high-AVA (H-AVA, 229.56 mg/kg) and low-AVA (L-AVA, 32.69 mg/kg).
Study: NCT02351323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine (Pharmacological doses)
Description: 30 grams/day of glutamine for 12-14 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle change
Description: Lifestyle change as recommended by Registered Dietitian

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle change
Description: Lifestyle change as recommended by Registered Dietitian
Study: NCT02053025

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: mycoprotein

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: control protein
Study: NCT01349894

Intervention type: DEVICE
Intervention: SNaP® Wound Care System
Description: Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
Study: NCT03184896

Intervention type: PROCEDURE
Intervention: Hip Fracture Surgery
Description: Hip Fracture Surgery
Study: NCT01650519

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV ibuprofen
Description: 800 mg intravenous ibuprofen administered intravenously over 10 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV ketorolac
Description: 30 mg ketorolac for patients \< 65 years of age (15 mg ketorolac for patients \> 65 years of age) administered intravenously over no less than 15 seconds
Study: NCT00583232

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stable isotope infusions
Description: Stable isotope infusion will be given via an intravenous catheter. Subjects will receive a priming dose and a continuous dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stable isotope infusions
Description: Stable isotope infusion will be given via an intravenous catheter. Subjects will receive a priming dose and a continuous dose.
Study: NCT00526383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Description: antidepressant version medical dispositive

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tricyclic antidepressants
Description: antidepressant version medical dispositive
Study: NCT04488367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: 10 mg/kg IV TXA in the ED, repeat doses before skin incision and in PACU

Intervention type: DRUG
Group type: OTHER
Intervention: Normal Saline
Description: 100 mL 0.9% normal saline in the ED, 10 mg/kg IV TXA before skin incision and in PACU
Study: NCT01291316

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonazepam
Description: clonazepam, 1 mg, single oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tolterodine
Description: Tolterodine 1,37mg, single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clobazam
Description: clobazam 20 mg, single oral dose
Study: NCT02885493

Intervention type: BEHAVIORAL
Intervention: tests

Intervention type: BEHAVIORAL
Intervention: tests
Study: NCT03679767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Retifanlimab administered intravenously at 500 mg every 4 weeks
Study: NCT00954512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Study: NCT01488422

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Reduction
Description: We are comparing 2 well-studied approaches to stress reduction. All participants will receive stress reduction instructions that have already been proven to effectively reduce stress. Our goal is to compare the neural mechanisms associated with both approaches.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Reduction
Description: We are comparing 2 well-studied approaches to stress reduction. All participants will receive stress reduction instructions that have already been proven to effectively reduce stress. Our goal is to compare the neural mechanisms associated with both approaches.
Study: NCT04253639

Intervention type: OTHER
Intervention: Questionnaires
Description: Patients must fill questionnaires to collect socio-demographics, aetiology and characteristics of pain, efficacy and tolerance regarding the TENS.~Study sites must fill questionnaires to collect information regarding the type of pain management centre, the characteristics of the clinician, the characteristics of the TENS prescribed.
Study: NCT02048566

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ImaCor PM
Description: The ImaCor ClariTEE (hTEE) device is a transesophageal echocardiography system. It produces a single-plane two-dimensional image. The ImaCor probe is a 5.5 mm detachable probe; it can remain in situ for up to 72h and allows for reassessment of the patient's hemodynamic progress and the effect of selected interventions at any time. The probe is connected to a dedicated echocardiographic system which allows the for the recording of digital loops and performance of basic two-dimensional measurements. ImaCorPM subjects will receive echocardiography-guided hemodynamic management (hTEE) at the time of inclusion, at the time of occurrence of defined new organ system deterioration and/or at least every 4 hours during the first 72h after study inclusion or until one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ImaCor SM
Description: The ImaCor ClariTEE (hTEE) device is a transesophageal echocardiography system. It produces a single-plane two-dimensional image. The ImaCor probe is a 5.5 mm detachable probe; it can remain in situ for up to 72h and allows for reassessment of the patient's hemodynamic progress and the effect of selected interventions at any time. The probe is connected to a dedicated echocardiographic system which allows the for the recording of digital loops and performance of basic two-dimensional measurements. ImaCorSM subjects will receive echocardiography-guided hemodynamic management (hTEE) at the time of inclusion, follow-up assessment intervals are at the discretion of the treating physician for the first 72h after study inclusion. hTEE monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control PM
Description: Group Control protocolized monitoring (ControlPM) will receive any hemodynamic monitoring of choice of the treating physician except ImaCor. Protocolized hemodynamic assessments will be performed at the time of inclusion, at the time of occurrence of defined new organ system deterioration or at least every 4 hours for the first 72h after study inclusion. Protocolized monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control SM
Description: Group Control standard monitoring (ControlSM) will receive any hemodynamic monitoring of choice of the treating physician except ImaCor. Protocolized hemodynamic assessments will be performed at the time of inclusion, follow-up measurement intervals are at the discretion of the treating physician for the first 72h. Data collection from standard monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
Study: NCT03829618

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical lidocaine
Description: 1% lidocaine topically applied in 4 mL aliquots

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebuliser solution
Description: 2% lidocaine dose at 2 mg/kg (max 160 mg) applied via jet nebulizer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebuliser Suspension
Description: 2% lidocaine dosed at 2 mg/kg (max 160 mg) applied via vibrating mesh nebulizer
Study: NCT03340220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XPF-008
Description: Capsule filled with XEN1101

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline Cellulose
Description: Placebo capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XPF-010
Description: Capsule filled with XEN1101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XPF-010
Description: Capsule filled with XEN1101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole 400mg
Description: Oral
Study: NCT01813214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Study: NCT03726294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBM-BMX softgel capsules
Description: Patients will initially receive NBM-BMX orally once a day at 100 mg per day.
Study: NCT03088163

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diffusion weighted magnetic resonance imaging
Description: The enrolled colorectal liver metastases patients will receive DWI-MRI screening to evaluate the liver metastases before the chemotherapy, after the first cycle of chemotherapy and in the regular efficacy evaluation time, respectively.
Study: NCT03679767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Retifanlimab administered intravenously at 500 mg every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Retifanlimab administered intravenously at 500 mg every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Retifanlimab administered intravenously at 500 mg every 4 weeks
Study: NCT03653832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients will commence intravenous infusion of open-label study drug according to a weight-based dose regimen as early as possible post-randomisation, and within a maximum of two hours.~Bedside clinical staff will transition patients to achieve sedation with the allocated α2-agonist agent as quickly as clinically feasible and safe, to replicate the way these drugs would be used in routine practice. Additional opiate will be used for analgesia using clinical judgement. Once established, additional propofol will only be used when the maximum α2-agonist dose is reached or because cardiovascular or other side-effects limit dose escalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Patients will commence intravenous infusion of open-label study drug according to a weight-based dose regimen as early as possible post-randomisation, and within a maximum of two hours.~Bedside clinical staff will transition patients to achieve sedation with the allocated α2-agonist agent as quickly as clinically feasible and safe, to replicate the way these drugs would be used in routine practice. Additional opiate will be used for analgesia using clinical judgement. Once established, additional propofol will only be used when the maximum α2-agonist dose is reached or because cardiovascular or other side-effects limit dose escalation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Patients will continue to receive intravenous propofol according to current usual care.